Depression is today’s most prevalent mental health disorder and the leading cause of disability worldwide. Painful both mentally and physically, the onset of the disease is slow and gradual, with highly variable symptoms that manifest differently from person to person, making it a challenge to identify for both medical practitioners and those close to the individual.
Burdens of Depression: The Individual
atai Life Sciences announces the launch of PsyProtix, to develop a precision psychiatry approach for Treatment-Resistant Depression (TRD)
atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced…
JOIN THE ATAI #INSIGHTNETWORK